July 16, 2020 / 2:44 PM / 22 days ago

Abbott CEO expects high demand for antibody tests even after approved COVID-19 vaccine

(Reuters) - Abbott Laboratories (ABT.N) expects to see higher demand for serology and antibody testing for the new coronavirus, even after a vaccine becomes available, Chief Executive Officer Robert Ford said on a post-earnings conference call on Thursday.

The company, which has two antibody tests authorized for emergency use in the United States, said testing volumes in its underlying diagnostics unit, excluding COVID-19 tests, also rebounded to about 90% of pre-COVID levels by the end of the second quarter.

(The story corrects CEO name in paragraph 1.)

Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below